Rajnish Wellness Ltd (RAJNISH)

Loading page…

Rajnish Wellness Ltd (RAJNISH) · mywealthgrid

About

Rajnish Wellness Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹1

Market cap

₹37 Cr

P/E

—

P/B

0.4×

Dividend yield

ROE

-6.7%

ROCE

-8.8%

Debt / equity

OPM

-6.5%

EPS (TTM)

₹-0.1

Book value

₹1.0

52-week high

—

52-week low

—

915 historical price candles were omitted because the exchange source has not been verified.

₹0.4-5.3%1Y

Quick read

rule-based

Pros

+Revenue CAGR of 60.4% over the last 5 years
+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of -1.8% (3-yr avg)
−Low promoter holding of 9.2%

Research score

Structured signal from quality, growth, valuation and momentum.

75/100

Business quality: 25
Growth: 100
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	13	26	26	77	49	142
COGS	15	24	23	71	46	138
Gross profit	-2	2	3	6	3	4
	1	3	4	4	3	13
	-3	-0	-1	2	0	-9
OPM %	-23.8%	-0.7%	-4.3%	2.6%	0%	-6.5%
Depreciation	0	0	0	0	0	0
Interest	0	0	0	1	0	0
	4	1	2	0	1	1
Profit before tax	0	0	1	1	0	-8
Tax	0	0	0	0	0	-2
Tax %	16.7%	14.9%	27%	28.3%	26.1%	-25.3%
	0	0	0	1	0	-6
PAT margin %	0.8%	1.5%	1.8%	1.3%	0.4%	-4.4%
EPS (₹)	—	—	—	—	—	0.1
EPS adjusted (₹)	0	0	0	0	0	-0.1
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	5	11	77	77	77	102
Reserves	17	12	6	7	7	1
Minority interest	0	—	—	—	—	—
	9	0	0	1	0	0
	4	13	16	21	7	6
Total equity & liabilities	35	35	99	106	91	109
	0	0	0	0	0	0
CWIP	—	—	—	—	—	0
Investments	0	0	0	0	0	8
	35	35	99	106	91	101
Total assets	35	35	99	106	91	109

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	-0	-62	2	-4	-9
	0	-0	-0	-0	9	-7
	-0	1	62	-2	-5	25
Net cash flow	0	1	-1	-0	0	9
Free cash flow	0	—	—	2	-4	-9
CFO / Operating profit %	—	—	—	86.3%	—	—

Compounded sales growth

7 years: —
5 years: 60%
3 years: 76%
1 year: 192%

Return on equity

7 years: —
5 years: -1%
3 years: -2%
Last year: -6%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	-13.3%	9.3%	10.5%	7.4%	5.8%	2.7%
EBITDA margin %	-23.8%	-0.7%	-4.3%	2.6%	0%	-6.5%
EBIT margin %	-24.2%	-0.7%	-4.3%	2.5%	-0%	-6.5%
PAT margin %	0.8%	1.5%	1.8%	1.3%	0.4%	-4.4%
Working capital
Receivable days	460	224	285	160	201	50
Inventory days	27	32	59	48	79	35
Payable days	50	17	55	78	30	0
NWC days	436	238	289	130	249	85
Leverage
Current ratio	2.65	8.63	6.58	4.86	16.78	25.12
Debt to EBITDA	—	—	—	0.6	—	—
Debt to equity	0.4	0	0	0.01	0	0
Interest coverage	1.4	2.6	16.7	3.8	1.9	—
Asset turnover	0.39	0.75	0.26	0.72	0.53	1.31
Return ratios
Return on assets %	0.3%	1.1%	0.5%	1%	0.2%	-5.8%
Return on capital employed %	1.9%	2.8%	1.1%	2.1%	0.6%	-8.8%
Return on equity %	0.5%	1.8%	0.6%	1.2%	0.2%	-6.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	16.24%	16.24%	16.24%	16.24%	16.24%	7.41%	7.41%	7.41%	9.16%	9.16%	9.16%	9.16%
	0%	0%	1.09%	1.2%	0.2%	0%	0.57%	0.57%	0.43%	0.43%	0.43%	0.43%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	83.76%	83.76%	82.67%	82.56%	83.56%	92.59%	92.02%	92.02%	90.41%	90.41%	90.41%	90.41%
No. of shareholders	—	—	—	—	—	—	—	—	1,65,636	1,62,955	1,60,259	1,58,442

Promoter holding down 7.08 percentage points since Sep 2023.

307 deals · 10 Aug 2021 – 30 Jun 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 Jun 2026	RIKANT PITTIE	Bulk	BSE	Sell	66,80,000	₹0.41	₹0.27 Cr
7 May 2026	JASMITSINGHCHANDHOK	Bulk	BSE	Sell	76,00,000	₹0.45	₹0.34 Cr
6 May 2026	JASMITSINGHCHANDHOK	Bulk	BSE	Sell	1,06,80,378	₹0.47	₹0.50 Cr
12 Mar 2026	JASMITSINGHCHANDHOK	Bulk	BSE	Buy	65,56,610	₹0.52	₹0.34 Cr
23 Jan 2026	SAROJ KUMAR KUNDU	Bulk	BSE	Sell	54,27,229	₹0.48	₹0.26 Cr
13 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Sell	56,21,170	₹0.51	₹0.29 Cr
13 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Buy	50,65,286	₹0.52	₹0.26 Cr
12 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Buy	72,70,069	₹0.51	₹0.37 Cr
12 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Sell	62,20,069	₹0.50	₹0.31 Cr
26 Dec 2025	RAJPUT RAVINDRA B	Bulk	BSE	Sell	75,00,000	₹0.54	₹0.41 Cr

1–10 of 307

1 / 31

Mr. RAJNISHKUMAR SURENDRAPRASAD SINGHExecutive Director-Chairperson-MD
Ms. MONAM KAPOORNon-Executive - Independent Director
Ms. PREETINon-Executive - Independent Director
Ms. SWATI JAINNon-Executive - Independent Director
Ms. SALONI MEHRANon-Executive - Non Independent Director
Mihir Shrenik PatwaChief Financial Officer
Ms. Anupma KashyapCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Rajnish Wellness Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results13 Aug 2026

2

Face value ₹2 → ₹110 Jan 2023 · ex-date
Face value ₹10 → ₹221 Jul 2022 · ex-date

2

Bonus 2:121 Jul 2022 · ex-date
Bonus 5:423 Dec 2021 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

66 announcementsExport CSV

31 Aug 2026, 5:30 pmOthers

Board Meeting Outcome for Outcome Of Board Meeting Held On Monday The 31St Of August, 2026 Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	-13.3%	9.3%	10.5%	7.4%	5.8%	2.7%
EBITDA margin %	-23.8%	-0.7%	-4.3%	2.6%	0%	-6.5%
EBIT margin %	-24.2%	-0.7%	-4.3%	2.5%	-0%	-6.5%
PAT margin %	0.8%	1.5%	1.8%	1.3%	0.4%	-4.4%
Working capital
Receivable days	460	224	285	160	201	50
Inventory days	27	32	59	48	79	35
Payable days	50	17	55	78	30	0
NWC days	436	238	289	130	249	85
Leverage
Current ratio	2.65	8.63	6.58	4.86	16.78	25.12
Debt to EBITDA	—	—	—	0.6	—	—
Debt to equity	0.4	0	0	0.01	0	0
Interest coverage	1.4	2.6	16.7	3.8	1.9	—
Asset turnover	0.39	0.75	0.26	0.72	0.53	1.31
Return ratios
Return on assets %	0.3%	1.1%	0.5%	1%	0.2%	-5.8%
Return on capital employed %	1.9%	2.8%	1.1%	2.1%	0.6%	-8.8%
Return on equity %	0.5%	1.8%	0.6%	1.2%	0.2%	-6.1%

Date	Category	Subject	Filing
31 Aug 2026, 5:30 pm	Others Outcome without intimation	Board Meeting Outcome for Outcome Of Board Meeting Held On Monday The 31St Of August, 2026 Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.	PDF
14 Aug 2026, 11:26 am	Company Update General	Submission Of Newspaper Clippings Of Un-Audited Financial Results For Quarter Ended 30Th June, 2026	PDF
13 Aug 2026, 5:44 pm	Result Financial Results	Un-Audited Standalone Financial Results For The Quarter Ended 30Th June, 2026	PDF
13 Aug 2026, 5:21 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting Held Today On Thursday The 13Th August, 2026	PDF
10 Aug 2026, 4:20 pm	Board Meeting	Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements, 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter And Year Ended 30Th June, 2026 And Other Matters	PDF
13 Jul 2026, 5:01 pm	Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	PDF
25 Jun 2026, 5:09 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
1 Jun 2026, 3:00 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF

Rajnish Wellness Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Stock splits2

Bonus issues2

Announcements

No fund holdings on record

Board meetings1

Stock splits2

Bonus issues2

Ratio timeline

Not in the F&O segment

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

2

2

1

2

2